Description:

CALGB: 40101 ON-STUDY FORM Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer NCT00041119 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A4E097B4-CDDD-18B4-E034-080020C9C0E0

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A4E097B4-CDDD-18B4-E034-080020C9C0E0

Keywords:
Versions (2) ▾
  1. 8/26/12
  2. 3/23/15
Uploaded on:

March 23, 2015

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Breast Cancer NCT00041119

Continue to next page

  1. StudyEvent: CALGB: 40101 ON-STUDY FORM
    1. Continue to next page
Header
Amended data?
Patient data
Menopausal Status
Tumor Laterality (mark one with an X)
Receptor Status, ER (If measured in fmols/mg cytosol protein >= 10 is positive. If other measures are used apply institutional standards; borderline results should be reported as positive)
Receptor Status, PgR (mark one with an X)
Histologic Grade (combined histologic grade is used according to SBR/ELSTON classification.)
HER-2 neu Status
cm
Prior hormonal therapy? (do not include steroids given with chemotherapy)
Tamoxifen
Raloxifene
Prior adjuvant chemotherapy for this malignancy? (include pre-op chemotherapy at diagnosis)
mg/dl
mg/dl
Type of biopsy (mark one with an X)
Most extensive primary surgery (mark one with an X)
Sentinel node biopsy
If done, sentinel node biopsy results (per protocol)
Was axillary dissection performed?